Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target

Morgan Stanley reiterated Overweight on Eli Lilly with a $1,313 price target (market cap $803B) and sees ~6% upside to 2026 estimates; Jefferies and Leerink also reiterated $1,300 and $1,296 targets respectively, while the stock trades around $897 vs an InvestingPro fair value of $1,013. Prescription trends show Mounjaro at ~729,600 total and 359,900 new scripts (week of Mar 20) vs ~752,000/370,400 the prior week; Zepbound roughly stable at ~608,600/326,400; oral Wegovy reached ~94,700 total and 86,400 new prescriptions in its 11th week. Clinical and fundamentals are supportive: Eli Lilly reported ~45% revenue growth LTM and a PEG of 0.41, ADlong Phase 3b Ebglyss data showed 94% achieved 75% reduction and 75% achieved 90% improvement (up to four years), and retatrutide 12 mg cut A1c by 1.9% vs 0.8% placebo over 40 weeks — overall bullish for LLY with potential single-digit upside implied by analysts.

Analysis

Oral GLP-style therapies are reshaping the addressable market by lowering the friction to start treatment — the main second-order effect is not just share shifts between incumbents but a larger cohort of chronic users (primary care starts, telehealth-origin patients) who were previously non-starters for injectables. That amplitude expansion favors firms that control both product mix and distribution/real-world data flows because lifetime revenue per patient will be driven as much by adherence and switch rates as by headline efficacy.

Competitive dynamics will bifurcate winners: manufacturers with scalable small-molecule oral supply chains and strong payer contracting teams will capture rapid share gains, while biologics-heavy players retain pricing power where injectables face capacity-constrained economics. Data integrators and analytics providers that remove channel blind spots (telehealth, cash-pay) will see outsized commercial value — imperfect visibility today creates trading volatility on headline weekly scripts that will settle as integrations complete.

Primary near-term risks are payer pushback on list/pricing and noisy prescription data that can create false signals for investor positioning; both can flip sentiment inside a single quarter. Over 6–24 months, regulatory safety reads from next-gen molecules and evidence on real-world persistence will be the decisive catalysts that either compress multiples or justify premium growth assumptions.

Given the landscape, the convexity lies in option-backed exposure to the better-positioned manufacturers plus selective exposure to data/outsourcing vendors that monetize measurement. Trades should size for outcome risk, use pairs to neutralize macro beta, and explicitly budget for a potential rapid repricing if payers or regulators step in.

Key Decisions for Investors

• Long LLY via a 12–18 month call spread (buy near-the-money calls, sell ~25% OTM calls) — targeted upside 20–35% if adoption/persistence trends remain robust; max loss = premium paid, use 3–5% portfolio allocation.
• Pair trade: long LLY / short NVO equal notional, 6–12 month horizon — play portfolio breadth and margin capture vs pure-play oral rollouts; target relative outperformance of 5–15%, stop-loss if combined position moves against you by 8%.
• Buy a tactical 9–12 month position in IQV (small size, 1–2% portfolio) to play improving visibility monetization as telehealth/cash channels integrate; downside is execution/integration delays — limit drawdown with a 25% stop.
• Protective hedge: purchase a 6–12 month put or put spread on LLY sized to cover 30–50% of the long exposure if funding the call spread — caps downside from sudden payer/regulatory shocks while keeping upside optionality.